Previous projects
This is an archive of CELT Global Health projects, where our work within the research is complete.
AGILE - Clinical trial platform
This trial is now complete. The platform was a new type of study designed for pandemic drug testing, a world-first for infectious diseases, capable of testing multiple potential treatments in parallel and speeding up testing by pooling control data across patient groups.
An injectable implant providing long-acting drug delivery for the treatment of chronic disease
Our part in this research is now complete. We developed a new drug delivery system that could be easily injected into the body and would provide long-acting drug release.
OPTIMIZE
The OPTIMIZE project is now complete. It was an international collaboration of partners with a shared ambition to optimise the delivery and use of antiretroviral drugs. CELT Global Health investigators were involved in development of oral formulations of utility in simplification of adult and paediatric drug delivery.
Pharmacological strategies to use the levonorgestrel implant in HIV-infected women
Our part in this research is complete. The work aimed to determine the impact of pharmacogenetics and drug-drug interaction on the pharmacokinetics of contraceptives delivered via subcutaneous implants.
Repurposing approved drugs as potent antiviral combinations to treat COVID-19 disease
CELT Global Health's part in this research is now complete. Supporting a collaboration between Queens University Belfast, University of Oxford and CELT Global Health investigators, this project aims to validate a drug screening pipeline platform for robust and rapid progression of drug combinations against Sars-CoV-2 through the preclinical pipeline.
Target exposures of rifapentine for long-acting formulations
CELT Global Health's part in this research is now complete. Supporting a collaboration with Johns Hopkins University, this work served to better understand the compatibility of tuberculosis treatments with long-acting drug delivery.